Isaac J. Bright, MD, Joins Synthetic Biologics as Vice President, Corporate Development

Company Expands Strategic Partnering Efforts of Late-Stage GI Microbiome-Focused Clinical Programs

ROCKVILLE, Md., May 11, 2016 -- (Healthcare Sales & Marketing Network) -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on ... Biopharmaceuticals, Gastroenterology, PersonnelSynthetic Biologics, gut microbiome, irritable bowel syndrome

Source: HSMN NewsFeed - May 11, 2016 Category: Pharmaceuticals Source Type: news